This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
IGF-1 in Friedreich’s Ataxia – proof-of-concept trial
Cerebellum & Ataxias Open Access 04 July 2014
-
Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
BMC Neurology Open Access 24 August 2009
-
Autosomal recessive cerebellar ataxias
Orphanet Journal of Rare Diseases Open Access 17 November 2006
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Carvajal, J.J. et al. Nature Genet. 14, 157–162 (1996).
Campuzano, V. et al. Science 271, 1423–1427 (1996).
Montermini, L. et al. Am. J. Hum. Genet. 57, 1061–1067 (1995).
Ishihara, H. et al. J. Biol. Cell. 271, 23611–23614 (1996).
Ansari-Lari, M.A. et al. Genome Res. 6, 314–326 (1996).
Carvajal, J.J. et al. Hum. Mol. Genet. 4, 1411–1419 (1995).
Borrow, J. et al. Nature Genet. 14, 33–41 (1996).
Cohen, A.J. et al. Cancer Res. 56, 831–839 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cossée, M., Campuzano, V., Koutnikova, H. et al. Frataxin fracas. Nat Genet 15, 337–338 (1997). https://doi.org/10.1038/ng0497-337
Issue Date:
DOI: https://doi.org/10.1038/ng0497-337
This article is cited by
-
The inherited cerebellar ataxias: an update
Journal of Neurology (2023)
-
Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich’s Ataxia Mouse Model
Neurotherapeutics (2019)
-
IGF-1 in Friedreich’s Ataxia – proof-of-concept trial
Cerebellum & Ataxias (2014)
-
Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial
The Cerebellum (2013)
-
Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
BMC Neurology (2009)